Trial Profile
An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2015
Price :
$35
*
At a glance
- Drugs PEG-haemoglobin carbon monoxide (Primary)
- Indications Hypoxia
- Focus Adverse reactions
- Sponsors Prolong Pharmaceuticals
- 26 Oct 2013 New trial record
- 03 Oct 2013 Results have been presented at the Joint Conference of the International Federation of Artificial Organs and the Japan Society of Artificial Organs according to a Prolong Pharmaceuticals media release. Results were also reported in the media release.
- 03 Oct 2013 Status changed from recruiting to completed based on information reported in a Prolong Pharmaceuticals media release.